The source record establishes a priced BPC-157 vial listing and a recurring-care agreement. It does not independently establish patient eligibility, fulfilled orders or clinical results. Pepti belongs in a document-based service comparison if those boundaries stay visible. Read the supply cycle and refund conditions alongside the advertised package before deciding what the first payment would commit you to.
Advertised starting price
$209 for the checked 5 mg vial option
Billing basis
Automatic refill subscription; approximately 28-day supply, not a calendar month
The strongest supported finding is an itemized BPC-157 order example with a separate clinical-review charge. That clarity makes the transaction easier to inspect, but it does not independently establish licenses, patient eligibility or treatment benefit. Preserve the fee-at-review-start rule and the distinct pharmacy agreement when using this offer in a comparison; neither should disappear behind the vial’s advertised figure.
Published order example
$134: $39 review + $80 vial + $15 shipping
Billing model
Medical review per order; medication billed separately by pharmacy
The catalog record supports a review of CoreAge as a provider brand, with BPC-157 availability left unverified. That limited conclusion is more useful than borrowing a price from another product or reading general peptide coverage as inventory. The source disagreement on renewals and consultation refunds remains part of the assessment, rather than a detail to smooth away.
Review scope
Provider brand; target-product availability not verified
The strongest documented facts are narrow: a named injectable route and two displayed package options. MyNuvara’s broader platform statements do not answer every product-level question. Read the prescription pathway, recurring agreement and refund boundary as separate evidence, and keep the provider’s marketing claims out of the conclusion about what BPC-157 can do.
Advertised starting price
$237 monthly option; $463 three-month injectable option, as displayed
Promise provides unusually explicit first-versus-renewal pricing for the reviewed single product. That makes it possible to ask concrete commercial questions, without treating the service as evidence of BPC-157 effectiveness. Compare published provider terms, record a complete written quote and retain unanswered questions for a clinician. This is a documentary review, not firsthand care experience or a clinical score.
Advertised starting price
Single BPC-157: $229 first; $279 per 28-day renewal
Billing basis
Recurring subscription every 28 days; higher renewal price
State and pharmacy match
Exact product-state eligibility and dispensing pharmacy/license not independently verified
The strongest parts of the public record are the geographic scope and the distinction between consultation, review and medication. Those make the service easier to compare. They do not independently verify a dispensing assignment or establish that a recovery claim will hold for a particular patient.
Published single-product price
$199 per bottle, before the $49 medication review; not a monthly rate.
Extra order charge
One $49 medication review per order; the consultation itself is described as free.
Pharmacy check
Provider says a licensed U.S.503A pharmacy fills the prescription; individual facility and licenses not independently verified.
The published package is more specific than a brand-only peptide claim. The remaining work is important: establish the actual pharmacy, reconcile refund wording and distinguish the provider’s clinical language from the evidence supporting it. An inclusive price is not an independent clinical verification.
Product-page price
$261 for the one-month option; $667 total for the displayed three-month option. These are advertised package labels, not a guaranteed prescription duration.
Pharmacy and state checks
The site refers to503A and503B pharmacies generally. The specific dispensing assignment and state match were not independently verified.
Women-specific copy can make an offer easier to find without showing what the clinical assessment or dispensing pathway actually includes. Request the name of the professional responsible for review, the preparation being considered and the follow-up arrangement. This page evaluates those service questions; the reviewed documents do not support a women-specific clinical winner. Bring individual health questions to the clinician rather than expecting an audience category to resolve them.
Keep the decision and the purchase separate
Before a paid assessment or prepaid plan, ask what happens if no prescription is issued and which fees remain payable. If a wider women’s-health program is offered alongside BPC-157, request its separate scope and billing terms. The source-backed comparison should show what has been documented and what still needs confirmation. It should not imply that a provider’s wider catalog establishes personal suitability for a peptide.
How to narrow your shortlist
First, match the exact molecule and formulation. Ask whether the provider names the clinician and dispensing pharmacy, makes state coverage clear and publishes a full recurring cost. Do not turn an absent detail into a positive assumption.
Read the essential guide before treating similarly named products as equivalent, and keep the current availability distinctions alongside the provider’s claims.
Compare the commitment on equal terms
A monthly price, a 28-day refill and a three-month purchase can produce different payment schedules. Put the actual terms into the cost planner, including the introductory payment, consultation, follow-up and delivery.
What this comparison cannot establish
These are reviews of published information. They do not independently verify the quality of a dispensed product, show that a molecule works for a particular goal or replace a clinician’s assessment. Coverage is limited to the providers reviewed by this publication.
Use the question checklist to ask about missing details before providing payment or health information. Our methodology explains the comparison criteria and the distinction between editorial coverage and partner placements.